Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 97, showing 5 Applications out of 482 total, starting on record 36, ending on 40

# Protocol No Study Title Investigator(s) & Site(s)

36.

ECCT/24/02/04   IGHID 12333
    IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.   
Principal Investigator(s)
1. Chemtai Mungo
Site(s) in Kenya
Lumumba subcounty Hospital Kisumu
 
View

37.

ECCT/24/02/02   Sabin 003
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults   
Principal Investigator(s)
1. Prof. Videlis Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
View

38.

ECCT/24/02/06   INAVO122
    A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

39.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

40.

ECCT/24/01/03   Doxy Short Course
    A Phase 4 Study of a 3-Day Vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection.   
Principal Investigator(s)
1. Jackson Nyangaresi Nyandoro
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
2. KEMRI CCR-PHRD (Nairobi City county)
 
View